Spectrum of BRCA1/2 Mutations in Romanian Breast and Ovarian Cancer Patients.
BRCA mutations
BRCA1 mutations
BRCA2 mutations
breast cancer
ovarian cancer
Journal
International journal of environmental research and public health
ISSN: 1660-4601
Titre abrégé: Int J Environ Res Public Health
Pays: Switzerland
ID NLM: 101238455
Informations de publication
Date de publication:
04 04 2022
04 04 2022
Historique:
received:
03
02
2022
revised:
31
03
2022
accepted:
02
04
2022
entrez:
12
4
2022
pubmed:
13
4
2022
medline:
14
4
2022
Statut:
epublish
Résumé
Background: About 10,000 women are diagnosed with breast cancer and about 2000 women are diagnosed with ovarian cancer each year in Romania. There is an insufficient number of genetic studies in the Romanian population to identify patients at high risk of inherited breast and ovarian cancer. Methods: We evaluated 250 women of Romanian ethnicity with BC and 240 women of Romanian ethnicity with ovarian cancer for the presence of damaging germline mutations in breast cancer genes 1 and 2 (BRCA1 and BRCA2, respectively) using Next-Generation Sequencing (NGS) technology. Results: Of the 250 breast cancer patients, 47 carried a disease-predisposing BRCA mutation (30 patients (63.83%) with a BRCA1 mutation and 17 patients (36.17%) with a BRCA2 mutation). Of the 240 ovarian cancer patients, 60 carried a BRCA mutation (43 patients (72%) with a BRCA1 mutation and 17 patients (28%) with a BRCA2 mutation). In the BRCA1 gene, we identified 18 variants (4 in both patient groups (ovarian and breast cancer patients), 1 mutation variant in the BC patient group, and 13 mutation variants in the ovarian cancer patient group). In the BRCA2 gene, we identified 17 variants (1 variant in both ovarian and breast cancer patients, 6 distinct variants in BC patients, and 10 distinct variants in ovarian cancer patients). The prevailing mutation variants identified were c.3607C>T (BRCA1) (18 cases) followed by c.5266dupC (BRCA1) (17 cases) and c.9371A>T (BRCA2) (12 cases). The most prevalent mutation, BRCA1 c.3607C>T, which is less common in the Romanian population, was mainly associated with triple-negative BC and ovarian serous adenocarcinoma. Conclusion: The results of our analysis may help to establish specific variants of BRCA mutations in the Romanian population and identify individuals at high risk of hereditary breast and ovarian cancer syndrome by genetic testing.
Identifiants
pubmed: 35409996
pii: ijerph19074314
doi: 10.3390/ijerph19074314
pmc: PMC8998351
pii:
doi:
Substances chimiques
BRCA1 Protein
0
BRCA1 protein, human
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
Discov Med. 2011 Nov;12(66):445-53
pubmed: 22127115
Breast Cancer Res Treat. 2012 Jul;134(2):889-94
pubmed: 22739995
BMC Cancer. 2015 Jul 17;15:523
pubmed: 26183948
Ugeskr Laeger. 2006 Jun 12;168(24):2367-9
pubmed: 16822422
Cancer. 2015 Feb 1;121(3):372-8
pubmed: 25236687
Mol Biol Rep. 2012 Mar;39(3):2109-18
pubmed: 21643751
N Engl J Med. 1997 May 15;336(20):1401-8
pubmed: 9145676
Int J Cancer. 2004 Jul 10;110(5):683-6
pubmed: 15146557
Breast Cancer Res Treat. 2015 May;151(1):157-68
pubmed: 25863477
Science. 2003 Oct 24;302(5645):643-6
pubmed: 14576434
JAMA. 2006 Mar 22;295(12):1379-88
pubmed: 16551709
Oncol Rep. 2013 Sep;30(3):1019-29
pubmed: 23779253
J BUON. 2020 May-Jun;25(3):1337-1347
pubmed: 32862574
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Biomed Res Int. 2013;2013:928562
pubmed: 24312913
Nature. 2000 Aug 17;406(6797):747-52
pubmed: 10963602
Breast Cancer Res Treat. 2010 Dec;124(3):643-51
pubmed: 20204502
J Natl Cancer Inst. 2013 Jun 5;105(11):812-22
pubmed: 23628597
Am J Hum Genet. 1997 May;60(5):1013-20
pubmed: 9150148
Am J Hum Genet. 2003 May;72(5):1117-30
pubmed: 12677558
Cancer Res. 1999 Apr 15;59(8):2011-7
pubmed: 10213514
EPMA J. 2010 Sep;1(3):397-412
pubmed: 23199084